

## ASX Announcement

11 November 2024

### First OncoSil™ Treatment at Istituto Nazionale dei Tumori

**Sydney, Australia – 11 November 2024:** Pancreatic cancer treatment device company **OncoSil Medical Limited (ASX:OSL)** (“OncoSil” or “the Company”) is pleased to announce that the first OncoSil™ device has been successfully implanted on 8th November 2024 at the Istituto Nazionale dei Tumori, Milan, Italy. This landmark procedure marks a significant milestone in the treatment of locally advanced pancreatic cancer and strengthens OncoSil's presence within leading oncology centers across Europe.

The Istituto Nazionale dei Tumori is recognized as one of Europe’s premier cancer centers, known for its clinical excellence, pioneering research, and commitment to advancing cancer therapies. As a leader in cancer care, the institute plays a pivotal role in clinical innovation and provides cutting-edge treatments to patients worldwide. The institution's collaboration with OncoSil Medical underscores a shared mission to offer novel solutions and improve outcomes for patients with difficult-to-treat cancers.

**Nigel Lange, CEO & Managing Director of OncoSil Medical, said:**

*"This milestone represents a critical step forward in making the OncoSil™ device widely available to patients fighting pancreatic cancer. We are honored to collaborate with one of Europe's premier cancer institutions and to have such dedicated healthcare professionals delivering our innovative treatment. We look forward to continuing to transform the treatment landscape for this challenging disease."*

#### Authorisation & Additional Information

This announcement was authorised by the Chairman of OncoSil Medical Limited.

**For further information, please contact:**

<b>Mr. Nigel Lange</b> CEO & Managing Director E: <a href="mailto:nigel.lange@oncosil.com">nigel.lange@oncosil.com</a> T: +49 30 300 149 3043	<b>Mr. Christian Dal Cin</b> CFO & Company Secretary E: <a href="mailto:c.dalcin@acclime.com">c.dalcin@acclime.com</a> T: +61 3 9824 5254	<b>Ms. Julia Maguire</b> <b>The Capital Network</b> Media and Investor Enquiries E: <a href="mailto:julia@thecapitalnetwork.com.au">julia@thecapitalnetwork.com.au</a> T: +61 2 8999 3699
--	--	---

**About OncoSil Medical**

OncoSil Medical Limited (ASX:OSL) has developed a cancer treatment device, the OncoSil™ brachytherapy device, which is a critical component of a revolutionary brachytherapy treatment for locally advanced unresectable pancreatic cancer. This type of cancer is the 12<sup>th</sup> most common cancer in men and the 11<sup>th</sup> most common cancer in women across the globe, with some 500,000 new cases of pancreatic cancer detected every year. With pancreatic cancer typically diagnosed at a later stage, it has a poor prognosis for long-term survival<sup>1</sup>.

The OncoSil™ device delivers a targeted intratumoural placement of Phosphorous-32 (<sup>32</sup>P) in the treatment of locally advanced unresectable pancreatic cancer. This occurs via injection directly into a patient's pancreatic tumours under endoscopic ultrasound guidance and takes place in combination with gemcitabine-based chemotherapy.

The OncoSil™ device that has already received breakthrough device designation in the European Union, United Kingdom and United States for the treatment of locally advanced unresectable pancreatic cancer in combination with chemotherapy. CE Marking has additionally been granted for the OncoSil™ device, which can be marketed in the European Union, United Kingdom.

While clinical trials involving the OncoSil™ device continue to occur, the Company is simultaneously moving to commercialise this unique medical technology. It is currently approved for sale in 30+ countries including European Union, United Kingdom, Türkiye and Israel, with initial commercial pancreatic cancer treatments using the device already undertaken in Spain, Italy and Israel.

To learn more, please visit: [www.oncosil.com/](http://www.oncosil.com/)

**References:** 1. <https://www.wcrf.org/cancer-trends/pancreatic-cancer-statistics/>